https://orcid.org/0000-0002-5345-7421
References
- Mohan M, Buros A, Mathur P, et al. Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition disease. Am J Hematol. 2017;92(8):739–745.
- Preud'homme JL, Aucouturier P, Touchard G, et al. Monoclonal immunoglobulin deposition disease (Randall type). Relationship with structural abnormalities of immunoglobulin chains. Kidney Int. 1994;46(4):965–972.
- Kastritis E, Migkou M, Gavriatopoulou M, et al. Treatment of light chain deposition disease with bortezomib and dexamethasone. Haematologica. 2009;94(2):300–302.
- Minarik J, Scudla V, Tichy T, et al. Induction treatment of light chain deposition disease with bortezomib: rapid hematological response with persistence of renal involvement. Leuk Lymphoma. 2012;53(2):330–331.
- Joly F, Cohen C, Javaugue V, et al. Randall-type monoclonal immunoglobulin deposition disease: novel insights from a nationwide cohort study. Blood. 2019;133(6):576–587.
- Eby C, Blinder M. Hemostatic complications associated with paraproteinemias. Curr Hematol Rep. 2003;2(5):388–394.
- Uprichard J, Perry DJ. Factor X deficiency. Blood Rev. 2002;16(2):97–110.
- Patel G, Hari P, Szabo A, et al. Acquired factor X deficiency in light-chain (AL) amyloidosis is rare and associated with advanced disease. Hematol Oncol Stem Cell Ther. 2019;12(1):10–14.
- Thompson CA, Kyle R, Gertz M, et al. Systemic AL amyloidosis with acquired factor X deficiency: a study of perioperative bleeding risk and treatment outcomes in 60 patients. Am J Hematol. 2010; 85:171–173.
- Furie B, Voo L, McAdam KP, et al. Mechanism of factor X deficiency in systemic amyloidosis. N Engl J Med. 1981;304(14):827–830.
- Tashiro H, Shirasaki R, Watanabe M, et al. Direct Factor X sequestration by systemic amyloid lightchain amyloidosis. Clin Case Rep. 2018;6(3):513–515.
- Mumford AD, O'Donnell J, Gillmore JD, et al. Bleeding symptoms and coagulation abnormalities in 337 patients with AL-amyloidosis. B J of Haematol. 2000;110(2):454–460.
- Muczynski V, Aymé G, Regnault V, et al. Complex formation with pentraxin-2 regulates factor X plasma levels and macrophage interactions. Blood. 2017;129(17):2443–2454.
- Choufani EB, Sanchorawala V, Ernst T, et al. Acquired factor X deficiency in patients with amyloid light-chain amyloidosis: incidence, bleeding manifestations, and response to high-dose chemotherapy. Blood. 2001;97(6):1885–1887.